124 related articles for article (PubMed ID: 9589820)
1. Pharmacokinetic profile of cisapride 20 mg after once- and twice-daily dosing.
Zhou H; Herron J; Clyde C; Lee P; Mechlinski W; Pesco-Koplowitz L
Clin Ther; 1998; 20(2):292-8. PubMed ID: 9589820
[TBL] [Abstract][Full Text] [Related]
2. Bioavailability of three oral dosage forms of cisapride, a gastrointestinal stimulant agent.
Barone JA; Huang YC; Bierman RH; Colaizzi JL; Long JF; Kerr DA; Van Peer A; Woestenborghs R; Heykants J
Clin Pharm; 1987 Aug; 6(8):640-5. PubMed ID: 3691010
[TBL] [Abstract][Full Text] [Related]
3. Cisapride 20 mg b.d. for preventing symptoms of GERD induced by a provocative meal. The CIS-USA-89 Study Group.
Castell D; Silvers D; Littlejohn T; Orr W; Napolitano J; Oleka N; Jokubaitis L
Aliment Pharmacol Ther; 1999 Jun; 13(6):787-94. PubMed ID: 10383509
[TBL] [Abstract][Full Text] [Related]
4. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 Investigator Group.
Castell DO; Sigmund C; Patterson D; Lambert R; Hasner D; Clyde C; Zeldis JB
Am J Gastroenterol; 1998 Apr; 93(4):547-52. PubMed ID: 9576446
[TBL] [Abstract][Full Text] [Related]
5. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease.
Hatlebakk JG; Johnsson F; Vilien M; Carling L; Wetterhus S; Thøgersen T
Scand J Gastroenterol; 1997 Nov; 32(11):1100-6. PubMed ID: 9399390
[TBL] [Abstract][Full Text] [Related]
6. Cisapride and metoclopramide in the treatment of gastroesophageal reflux disease.
Arabehety JT; Leitão OR; Fassler S; Olarte M; Serrano C
Clin Ther; 1988; 10(4):421-8. PubMed ID: 3079010
[TBL] [Abstract][Full Text] [Related]
7. Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers.
Maya MT; Domingos CR; Guerreiro MT; Filipe AP; Morais JA
Eur J Drug Metab Pharmacokinet; 1998; 23(3):377-81. PubMed ID: 9842980
[TBL] [Abstract][Full Text] [Related]
8. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders.
McCallum RW; Prakash C; Campoli-Richards DM; Goa KL
Drugs; 1988 Dec; 36(6):652-81. PubMed ID: 3065057
[TBL] [Abstract][Full Text] [Related]
9. Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice.
Desta Z; Kivistö KT; Lilja JJ; Backman JT; Soukhova N; Neuvonen PJ; Flockhart DA
Br J Clin Pharmacol; 2001 Oct; 52(4):399-407. PubMed ID: 11678783
[TBL] [Abstract][Full Text] [Related]
10. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders.
Wiseman LR; Faulds D
Drugs; 1994 Jan; 47(1):116-52. PubMed ID: 7510617
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic characteristics of cisapride in elderly patients.
Yamamoto T; Takano K; Sanaka M; Kuyama Y; Yamanaka M; Koike Y; Mineshita S
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):432-4. PubMed ID: 9726696
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
13. Cisapride disposition in neonates and infants: in vivo reflection of cytochrome P450 3A4 ontogeny.
Kearns GL; Robinson PK; Wilson JT; Wilson-Costello D; Knight GR; Ward RM; van den Anker JN;
Clin Pharmacol Ther; 2003 Oct; 74(4):312-25. PubMed ID: 14534518
[TBL] [Abstract][Full Text] [Related]
14. A comparison of the pharmacokinetics of two dosing regimens of cisapride and their effects on corrected QT interval in premature infants.
Cools F; Benatar A; Bruneel E; Theyskens C; Bougatef A; Casteels A; Vandenplas Y
Eur J Clin Pharmacol; 2003 May; 59(1):17-22. PubMed ID: 12682804
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of a cisapride suppository and tablet formulation in healthy volunteers.
Hedner T; Hedner J; Gelin-Friberg A; Huang ML; Van de Poel S; Woestenborghs R; Van Peer A; Heykants J
Eur J Clin Pharmacol; 1990; 38(6):629-31. PubMed ID: 2373139
[TBL] [Abstract][Full Text] [Related]
16. Influence of grapefruit juice on cisapride pharmacokinetics.
Gross AS; Goh YD; Addison RS; Shenfield GM
Clin Pharmacol Ther; 1999 Apr; 65(4):395-401. PubMed ID: 10223776
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and suggested oral dosing regimen of cisapride: a study in healthy cats.
LeGrange SN; Boothe DM; Herndon S; Willard MD
J Am Anim Hosp Assoc; 1997; 33(6):517-23. PubMed ID: 9358420
[TBL] [Abstract][Full Text] [Related]
18. Aggravation of parkinsonian tremor by cisapride.
Sempere AP; Duarte J; Cabezas C; Clavería LE; Coria F
Clin Neuropharmacol; 1995 Feb; 18(1):76-8. PubMed ID: 8665538
[TBL] [Abstract][Full Text] [Related]
19. Prokinetic therapy in gastroesophageal reflux disease.
Champion MC
Can J Gastroenterol; 1997 Sep; 11 Suppl B():55B-65B. PubMed ID: 9347180
[TBL] [Abstract][Full Text] [Related]
20. Clinical considerations in GERD (gastroesophageal reflux disease) therapy: focus on cisapride.
Snape WJ
Am J Manag Care; 1997 May; 3(5):766-71. PubMed ID: 10184748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
